title: BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities.
abstract: The therapeutic activity of selective serotonin (5-HT) reuptake inhibitors (SSRIs) relies on long-term adaptation at pre- and post-synaptic levels. The sustained administration of SSRIs increases the serotonergic neurotransmission in response to a functional desensitization of the inhibitory 5-HT1A autoreceptor in the dorsal raphe. At nerve terminal such as the hippocampus, the enhancement of 5-HT availability increases brain-derived neurotrophic factor (BDNF) synthesis and signaling, a major event in the stimulation of adult neurogenesis. In physiological conditions, BDNF would be expressed at functionally relevant levels in neurons. However, the recent observation that SSRIs upregulate BDNF mRNA in primary cultures of astrocytes strongly suggest that the therapeutic activity of antidepressant drugs might result from an increase in BDNF synthesis in this cell type. In this study, by overexpressing BDNF in astrocytes, we balanced the ratio between astrocytic and neuronal BDNF raising the possibility that such manipulation could positively reverberate on anxiolytic-/antidepressant-like activities in transfected mice. Our results indicate that BDNF overexpression in hippocampal astrocytes produced anxiolytic-/antidepressant-like activity in the novelty suppressed feeding in relation with the stimulation of hippocampal neurogenesis whereas it did not potentiate the effects of the SSRI fluoxetine on these parameters. Moreover, overexpressing BDNF revealed the anxiolytic-like activity of fluoxetine in the elevated plus maze while attenuating 5-HT neurotransmission in response to a blunted downregulation of the 5-HT1A autoreceptor. These results emphasize an original role of hippocampal astrocytes in the synthesis of BDNF, which can act through neurogenesis-dependent and -independent mechanisms to regulate different facets of anxiolytic-like responses.
authors: Laboratoire de Neuropharmacologie EA3544, Faculté de Pharmacie, Université Paris-Sud, Châtenay-Malabry Cedex, France.
authors: G
authors: G
authors: Quesseveur
authors: D J
authors: DJ
authors: David
authors: M C
authors: MC
authors: Gaillard
authors: P
authors: P
authors: Pla
authors: M V
authors: MV
authors: Wu
authors: H T
authors: HT
authors: Nguyen
authors: V
authors: V
authors: Nicolas
authors: G
authors: G
authors: Auregan
authors: I
authors: I
authors: David
authors: A
authors: A
authors: Dranovsky
authors: P
authors: P
authors: Hantraye
authors: R
authors: R
authors: Hen
authors: A M
authors: AM
authors: Gardier
authors: N
authors: N
authors: Déglon
authors: B P
authors: BP
authors: Guiard
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000494:pharmacology; D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology; D001007:Anxiety / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D019208:Brain-Derived Neurotrophic Factor / Q000032:analysis / Q000378:metabolism* / Q000502:physiology; D003863:Depression / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D005473:Fluoxetine / Q000494:pharmacology; D015870:Gene Expression / Q000502:physiology; D006624:Hippocampus / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D008297:Male; D051379:Mice; D055495:Neurogenesis / Q000502:physiology*; D010879:Piperazines / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology
chemical_list: D018687:Antidepressive Agents, Second-Generation; D019208:Brain-Derived Neurotrophic Factor; D010879:Piperazines; D011725:Pyridines; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D005473:Fluoxetine; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin
references: Neuron. 2009 May 28;62(4):479-93
references: 19477151
references: J Neurosci. 1982 Dec;2(12):1786-92
references: 7143052
references: Stem Cells. 2008 Apr;26(4):979-87
references: 18203672
references: J Neurosci. 1995 Nov;15(11):7539-47
references: 7472505
references: World J Biol Psychiatry. 2012 Sep;13(6):402-12
references: 22175526
references: Neurosci Lett. 2012 Jan 24;507(2):127-32
references: 22178857
references: Neurochem Int. 2001 Jul;39(1):39-49
references: 11311448
references: J Neurosci. 1995 Oct;15(10):6856-67
references: 7472443
references: J Clin Psychiatry. 1990 Apr;51 Suppl:14-20; discussion 21
references: 2157700
references: J Neurosci. 2005 Feb 2;25(5):1089-94
references: 15689544
references: Eur Neuropsychopharmacol. 2009 Nov;19(11):796-805
references: 19616923
references: Brain Res Mol Brain Res. 2001 Sep 10;93(1):56-63
references: 11532338
references: Int J Neuropsychopharmacol. 2012 Apr;15(3):349-61
references: 21439106
references: Eur J Neurosci. 2011 Mar;33(6):1152-9
references: 21395859
references: Gene Ther. 2010 Oct;17(10):1294-308
references: 20463759
references: Cell Death Differ. 2012 Apr;19(4):582-91
references: 21979466
references: Psychopharmacology (Berl). 2011 Jul;216(1):75-84
references: 21301813
references: Mol Psychiatry. 2010 May;15(5):501-11
references: 18825147
references: Glia. 2009 Apr 15;57(6):667-79
references: 18942755
references: J Neurosci. 2002 Apr 15;22(8):3251-61
references: 11943826
references: Genes Brain Behav. 2007 Jul;6(5):482-90
references: 17156118
references: J Neurosci. 2000 Jan 15;20(2):771-82
references: 10632606
references: Int J Neuropsychopharmacol. 2009 Aug;12(7):905-15
references: 19236729
references: Neurosci Lett. 2010 Oct 22;484(1):12-6
references: 20692322
references: Mol Psychiatry. 2010 Jan;15(1):80-92
references: 19621014
references: J Neurosci. 2009 Jan 21;29(3):678-85
references: 19158294
references: J Cell Biol. 2008 Oct 20;183(2):213-21
references: 18852301
references: Brain Res. 1996 Feb 26;710(1-2):11-20
references: 8963648
references: Int J Dev Neurosci. 2007 Aug;25(5):293-7
references: 17582721
references: J Neurosci Methods. 2002 Mar 30;115(1):97-105
references: 11897369
references: Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15570-5
references: 18832146
references: Neuropsychopharmacology. 2009 Oct;34(11):2376-89
references: 19606083
references: Science. 2006 Oct 6;314(5796):140-3
references: 17023662
references: Brain Res Mol Brain Res. 2002 Dec 30;109(1-2):119-27
references: 12531521
references: Neuron. 2008 Aug 14;59(3):399-412
references: 18701066
references: Behav Brain Res. 2008 May 16;189(1):9-16
references: 18258314
references: Br J Pharmacol. 2012 Jul;166(6):1872-87
references: 22335772
references: Trends Pharmacol Sci. 1994 Feb;15(2):36-9
references: 7909396
references: J Comp Neurol. 1996 Nov 18;375(3):417-44
references: 8915840
references: J Neurochem. 2005 Dec;95(6):1713-23
references: 16219031
references: Mol Pharmacol. 2012 Feb;81(2):106-12
references: 22031471
references: Pharmacology. 2011;87(1-2):5-10
references: 21178384
references: Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8856-60
references: 7568031
references: J Neurosci Res. 2005 Aug 15;81(4):481-7
references: 15968642
references: J Mol Neurosci. 2012 Sep;48(1):167-75
references: 22581450
references: J Neurosci Res. 1998 Apr 15;52(2):149-58
references: 9579405
references: Mini Rev Med Chem. 2011 Jun;11(7):555-64
references: 21699486
references: Eur Neuropsychopharmacol. 2013 Mar;23(3):171-85
references: 22609317
references: Science. 2003 Aug 8;301(5634):805-9
references: 12907793
references: Synapse. 1987;1(5):470-80
references: 2905533
references: Trends Neurosci. 2009 Aug;32(8):421-31
references: 19615761
references: J Comp Neurol. 1995 Jun 26;357(2):296-317
references: 7665731
references: Neuron. 2010 Jan 14;65(1):40-52
references: 20152112
references: Neuropsychopharmacology. 2006 Aug;31(8):1616-26
references: 16395301
references: Brain Res Mol Brain Res. 1994 Sep;25(3-4):217-24
references: 7808220
references: Fundam Clin Pharmacol. 1996;10(1):16-27
references: 8900496
references: PLoS One. 2011 Apr 15;6(4):e17600
references: 21525974
references: Neurosci Lett. 2011 Sep 26;503(1):15-9
references: 21843601
references: J Neurochem. 2002 Dec;83(6):1525-8
references: 12472905
references: Int J Neuropsychopharmacol. 2012 Jun;15(5):631-43
references: 21733238
references: J Neurochem. 2002 Sep;82(6):1367-75
references: 12354284